ZA200309806B - Novel immunomodulating compounds. - Google Patents
Novel immunomodulating compounds. Download PDFInfo
- Publication number
- ZA200309806B ZA200309806B ZA200309806A ZA200309806A ZA200309806B ZA 200309806 B ZA200309806 B ZA 200309806B ZA 200309806 A ZA200309806 A ZA 200309806A ZA 200309806 A ZA200309806 A ZA 200309806A ZA 200309806 B ZA200309806 B ZA 200309806B
- Authority
- ZA
- South Africa
- Prior art keywords
- dihydro
- pyrazolo
- clquinolin
- acid
- benzoic acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 58
- 230000002519 immonomodulatory effect Effects 0.000 title claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- 239000005711 Benzoic acid Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 10
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 230000008901 benefit Effects 0.000 claims description 5
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 229940123828 CD80 antagonist Drugs 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- AMMPQWOKQYHCHO-UHFFFAOYSA-N 3-(4-hydrazinylphenyl)propanoic acid Chemical compound NNC1=CC=C(CCC(O)=O)C=C1 AMMPQWOKQYHCHO-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- DZUUSHCOMPROCJ-UHFFFAOYSA-N 4-hydrazinylbenzonitrile Chemical compound NNC1=CC=C(C#N)C=C1 DZUUSHCOMPROCJ-UHFFFAOYSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- XBZZDZFHFUDIQJ-UHFFFAOYSA-N methyl 4-oxo-2,3-dihydrothiochromene-3-carboxylate Chemical compound C1=CC=C2C(=O)C(C(=O)OC)CSC2=C1 XBZZDZFHFUDIQJ-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- HBDAXKJJDLLNKN-SXOMAYOGSA-N (5s)-1-[4-[(2r)-5,6-dioxo-1-(2-phenylethyl)piperazin-2-yl]butyl]-4-[2-(4-hydroxyphenyl)ethyl]-5-(2-methylpropyl)piperazine-2,3-dione Chemical compound C([C@H]1CCCCN2C[C@@H](N(C(=O)C2=O)CCC=2C=CC(O)=CC=2)CC(C)C)NC(=O)C(=O)N1CCC1=CC=CC=C1 HBDAXKJJDLLNKN-SXOMAYOGSA-N 0.000 description 1
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- PIYNUZCGMLCXKJ-UHFFFAOYSA-N 1,4-dioxane-2,6-dione Chemical compound O=C1COCC(=O)O1 PIYNUZCGMLCXKJ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CVQSWZMJOGOPAV-UHFFFAOYSA-N 2,3-dihydrothiochromen-4-one Chemical compound C1=CC=C2C(=O)CCSC2=C1 CVQSWZMJOGOPAV-UHFFFAOYSA-N 0.000 description 1
- OPDFEMWFKZVKSH-UHFFFAOYSA-N 2-chloro-4-hydrazinylbenzoic acid Chemical compound NNC1=CC=C(C(O)=O)C(Cl)=C1 OPDFEMWFKZVKSH-UHFFFAOYSA-N 0.000 description 1
- CUMAWIRZIUSYGJ-UHFFFAOYSA-N 2-chloro-4-hydrazinylbenzoic acid;hydrochloride Chemical compound Cl.NNC1=CC=C(C(O)=O)C(Cl)=C1 CUMAWIRZIUSYGJ-UHFFFAOYSA-N 0.000 description 1
- RMGBIMCGSUEIDZ-UHFFFAOYSA-N 4-(3-oxothiochromeno[4,3-c]pyrazol-2-yl)benzonitrile Chemical compound N1=C(C2=CC=CC=C2SC=2)C=2C(=O)N1C1=CC=C(C#N)C=C1 RMGBIMCGSUEIDZ-UHFFFAOYSA-N 0.000 description 1
- JITDLNZZJORVEU-UHFFFAOYSA-N 4-(4-methyl-3-oxochromeno[4,3-c]pyrazol-2-yl)benzoic acid Chemical compound O=C1C2=C(C)OC3=CC=CC=C3C2=NN1C1=CC=C(C(O)=O)C=C1 JITDLNZZJORVEU-UHFFFAOYSA-N 0.000 description 1
- PUUHZTVRVFYBRR-UHFFFAOYSA-N 4-(4-methyl-3-oxochromeno[4,3-c]pyrazol-2-yl)benzonitrile Chemical compound O=C1C2=C(C)OC3=CC=CC=C3C2=NN1C1=CC=C(C#N)C=C1 PUUHZTVRVFYBRR-UHFFFAOYSA-N 0.000 description 1
- WXOHKMNWMKZMND-UHFFFAOYSA-N 4-aminohydrocinnamic acid Chemical compound NC1=CC=C(CCC(O)=O)C=C1 WXOHKMNWMKZMND-UHFFFAOYSA-N 0.000 description 1
- PCNFLKVWBDNNOW-UHFFFAOYSA-N 4-hydrazinylbenzoic acid Chemical compound NNC1=CC=C(C(O)=O)C=C1 PCNFLKVWBDNNOW-UHFFFAOYSA-N 0.000 description 1
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical compound C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- XBQJYYCMDQOBJO-UHFFFAOYSA-N C1=C(Cl)C(C(=O)O)=CC=C1N1C(=O)C2=CNC3=CC=CC=C3C2=N1 Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1N1C(=O)C2=CNC3=CC=CC=C3C2=N1 XBQJYYCMDQOBJO-UHFFFAOYSA-N 0.000 description 1
- GFGRGWGLEBCPBG-UHFFFAOYSA-N C1=CC(C(=O)O)=CC=C1N1C(=O)C2=CNC3=C(Cl)C=CC=C3C2=N1 Chemical compound C1=CC(C(=O)O)=CC=C1N1C(=O)C2=CNC3=C(Cl)C=CC=C3C2=N1 GFGRGWGLEBCPBG-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- DWXQUAHMZWZXHP-UHFFFAOYSA-N ethyl 4-chloroquinoline-3-carboxylate Chemical compound C1=CC=CC2=C(Cl)C(C(=O)OCC)=CN=C21 DWXQUAHMZWZXHP-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- OBWFJXLKRAFEDI-UHFFFAOYSA-N methyl cyanoformate Chemical compound COC(=O)C#N OBWFJXLKRAFEDI-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102404A SE0102404D0 (sv) | 2001-07-04 | 2001-07-04 | Novel immunomodulating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200309806B true ZA200309806B (en) | 2004-12-20 |
Family
ID=20284743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200309806A ZA200309806B (en) | 2001-07-04 | 2003-12-19 | Novel immunomodulating compounds. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1409485B1 (fr) |
| JP (1) | JP2005501033A (fr) |
| CN (1) | CN1249063C (fr) |
| AT (1) | ATE324373T1 (fr) |
| AU (1) | AU2002315996B2 (fr) |
| BR (1) | BR0210776A (fr) |
| CA (1) | CA2451749A1 (fr) |
| DE (1) | DE60210977T2 (fr) |
| ES (1) | ES2258150T3 (fr) |
| HK (1) | HK1066809A1 (fr) |
| HR (1) | HRP20031055B1 (fr) |
| HU (1) | HUP0401204A3 (fr) |
| MX (1) | MXPA04000017A (fr) |
| NO (1) | NO20035684L (fr) |
| NZ (1) | NZ530316A (fr) |
| PL (1) | PL367637A1 (fr) |
| RU (1) | RU2004103079A (fr) |
| SE (1) | SE0102404D0 (fr) |
| WO (1) | WO2003004495A1 (fr) |
| YU (1) | YU101603A (fr) |
| ZA (1) | ZA200309806B (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10407316B2 (en) | 2014-07-08 | 2019-09-10 | Avertana Limited | Extraction of products from titanium-bearing minerals |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540081A (en) | 2002-11-22 | 2008-03-28 | Active Biotech Ab | Pyrazoloquinolines with immunomodulating activity |
| ATE425164T1 (de) | 2002-12-16 | 2009-03-15 | Active Biotech Ab | Tetrazyklische immunmodulierende verbindungen |
| GB0305876D0 (en) * | 2003-03-14 | 2003-04-16 | Avidex Ltd | Immuno inhibitory heterocyclic compounds |
| KR101133959B1 (ko) * | 2003-03-14 | 2012-04-09 | 메디진 아게 | 면역조절 헤테로고리 화합물 |
| GB0325644D0 (en) | 2003-11-04 | 2003-12-10 | Avidex Ltd | Immuno ihibitory pyrazolone compounds |
| EP1707567A4 (fr) * | 2004-01-14 | 2009-08-19 | Ajinomoto Kk | Nouveau compose a cycle fusionne |
| GB0411770D0 (en) * | 2004-05-26 | 2004-06-30 | Avidex Ltd | Immuno inhibitory heterocyclic compouds |
| ATE411318T1 (de) | 2004-08-09 | 2008-10-15 | Medigene Ltd | Immunmodulierende oxopyrazolocinnoline als cd80- inhibitoren |
| CN101863903B (zh) * | 2010-06-08 | 2014-03-12 | 沈阳药科大学 | 1,4-二氢噻吩并[3’,2’:5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物及其应用 |
| SG11201509411VA (en) * | 2013-06-24 | 2015-12-30 | Merck Patent Gmbh | Pyrazole compounds as modulators of fshr and uses thereof |
| EP2883883A1 (fr) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Cibles thérapeutiques et agents utiles dans le traitement des lésions ischémiques de reperfusion |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4268516A (en) * | 1978-10-11 | 1981-05-19 | Pfizer Inc. | [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents |
| US4312870A (en) * | 1979-06-21 | 1982-01-26 | Ciba-Geigy Corporation | Pyrazoloquinolines |
| GB8818895D0 (en) * | 1988-08-09 | 1988-09-14 | Boots Co Plc | Therapeutic agents |
| ZA895646B (en) * | 1988-08-09 | 1990-04-25 | Boots Co Plc | Therapeutic agents |
| SE8903564D0 (sv) * | 1989-10-26 | 1989-10-26 | Pharmacia Ab | New use condensed quinoline compound |
| HU9202510D0 (en) * | 1990-02-02 | 1992-10-28 | Boots Co Plc | Method for producing new 1-benzo-pyrano(4,3)pyrazole derivatives and those of 1-benzo-thiopyrano(4,3)pyrazole and pharmaceutical preparatives containing said compounds |
| AR006520A1 (es) * | 1996-03-20 | 1999-09-08 | Astra Pharma Prod | Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion. |
-
2001
- 2001-07-04 SE SE0102404A patent/SE0102404D0/xx unknown
-
2002
- 2002-07-02 BR BR0210776-7A patent/BR0210776A/pt not_active IP Right Cessation
- 2002-07-02 YU YU101603A patent/YU101603A/sh unknown
- 2002-07-02 CN CNB028132890A patent/CN1249063C/zh not_active Expired - Fee Related
- 2002-07-02 ES ES02746260T patent/ES2258150T3/es not_active Expired - Lifetime
- 2002-07-02 DE DE60210977T patent/DE60210977T2/de not_active Expired - Lifetime
- 2002-07-02 PL PL02367637A patent/PL367637A1/xx not_active Application Discontinuation
- 2002-07-02 CA CA002451749A patent/CA2451749A1/fr not_active Abandoned
- 2002-07-02 JP JP2003510662A patent/JP2005501033A/ja not_active Withdrawn
- 2002-07-02 EP EP02746260A patent/EP1409485B1/fr not_active Expired - Lifetime
- 2002-07-02 RU RU2004103079/04A patent/RU2004103079A/ru not_active Application Discontinuation
- 2002-07-02 AU AU2002315996A patent/AU2002315996B2/en not_active Ceased
- 2002-07-02 MX MXPA04000017A patent/MXPA04000017A/es active IP Right Grant
- 2002-07-02 AT AT02746260T patent/ATE324373T1/de not_active IP Right Cessation
- 2002-07-02 HU HU0401204A patent/HUP0401204A3/hu unknown
- 2002-07-02 NZ NZ530316A patent/NZ530316A/en unknown
- 2002-07-02 WO PCT/SE2002/001309 patent/WO2003004495A1/fr active IP Right Grant
-
2003
- 2003-12-17 HR HR20031055A patent/HRP20031055B1/xx not_active IP Right Cessation
- 2003-12-19 ZA ZA200309806A patent/ZA200309806B/en unknown
- 2003-12-19 NO NO20035684A patent/NO20035684L/no not_active Application Discontinuation
-
2004
- 2004-12-14 HK HK04109875A patent/HK1066809A1/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10407316B2 (en) | 2014-07-08 | 2019-09-10 | Avertana Limited | Extraction of products from titanium-bearing minerals |
Also Published As
| Publication number | Publication date |
|---|---|
| SE0102404D0 (sv) | 2001-07-04 |
| CN1249063C (zh) | 2006-04-05 |
| PL367637A1 (en) | 2005-03-07 |
| BR0210776A (pt) | 2004-07-20 |
| CA2451749A1 (fr) | 2003-01-16 |
| HUP0401204A2 (hu) | 2004-10-28 |
| EP1409485A1 (fr) | 2004-04-21 |
| RU2004103079A (ru) | 2005-06-10 |
| HK1066809A1 (en) | 2005-04-01 |
| WO2003004495A1 (fr) | 2003-01-16 |
| EP1409485B1 (fr) | 2006-04-26 |
| YU101603A (en) | 2006-05-25 |
| NO20035684L (no) | 2004-03-02 |
| DE60210977T2 (de) | 2006-09-21 |
| HRP20031055A2 (en) | 2004-06-30 |
| ES2258150T3 (es) | 2006-08-16 |
| MXPA04000017A (es) | 2004-05-21 |
| DE60210977D1 (de) | 2006-06-01 |
| NO20035684D0 (no) | 2003-12-19 |
| ATE324373T1 (de) | 2006-05-15 |
| JP2005501033A (ja) | 2005-01-13 |
| HRP20031055B1 (en) | 2008-01-31 |
| CN1522254A (zh) | 2004-08-18 |
| AU2002315996B2 (en) | 2007-11-29 |
| NZ530316A (en) | 2004-08-27 |
| HUP0401204A3 (en) | 2008-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR910007970B1 (ko) | 4h-1-벤조피란-4-온 유도체 또는 이의 염, 이의 제조방법 및 활성 성분으로서 이를 함유하는 약제학적 조성물 | |
| KR0126300B1 (ko) | 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체 | |
| KR910002583B1 (ko) | 피페라진 유도체 또는 이의 염, 이의 제조방법 및 활성 성분으로서 이를 함유하는 약제학적 조성물 | |
| US8153671B2 (en) | Heterotetracyclic compounds as TPO mimetics | |
| WO2007032466A1 (fr) | Composé hétérocyclique et procédé de production et utilisation de celui-ci | |
| KR20010072080A (ko) | 페닐아졸 화합물, 그의 제조 방법 및 고지혈증용 약제 | |
| ZA200309806B (en) | Novel immunomodulating compounds. | |
| AU2005305072A1 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| KR900004698B1 (ko) | 벤조티아졸 또는 기타 헤테로시클릭 측쇄를 갖는 옥소프탈라지닐 아세트산의 제조 | |
| WO1998022442A2 (fr) | Compositions pharmaceutiques contenant des composes de diaryl-cyclomethylenepyrazole et leur utilisation en tant qu'inhibiteurs de la cyclooxygenase i (cox i) | |
| AU2002315996A1 (en) | Novel immunomodulating compounds | |
| JP2010524913A (ja) | 炎症治療において有用なピラゾール | |
| JP2023553291A (ja) | Ｔｒｐｍ３媒介性障害を治療するためのアリール誘導体 | |
| US5889022A (en) | Indole, indoline and quinoline derivatives with 5HT1D (anti-depressive) activity | |
| KR910001285B1 (ko) | 오르토 융해된 피롤 유도체의 제조방법 | |
| US6642249B2 (en) | Immunomodulating compounds | |
| JPS62469A (ja) | 新規キノロン誘導体、そのエステルおよびその塩 | |
| TW201422596A (zh) | 新穎噁唑啶酮化合物 | |
| CA2578332A1 (fr) | Derives de pyrozoline, leur procede d'obtention et leur utilisation en tant qu'agents therapeutiques | |
| EP0511021A1 (fr) | Dérivés de thiazole | |
| JP2001513527A (ja) | アントラニル酸類似体 | |
| JPS604170A (ja) | キノロン誘導体 | |
| JP2587902B2 (ja) | 新規な１−フェニルビシクロ［２．２．２］オクタン誘導体、それらの製造法及びそれら化合物を含有する製剤組成物 | |
| JPH0460450B2 (fr) | ||
| JPS6228148B2 (fr) |